Takeda Acquires Celiac-Focused PvP Biologics in Deal Worth $330 Million

Three years after Takeda and San Diego-based PvP Biologics inked a $35 million deal to develop a novel treatment for celiac disease, the Japanese pharma company has exercised its option to acquire the company for $330 million.